Search clinical trials for: REGN5093

Total 30 results

Regeneron Pharmaceuticals

Active, not recruiting

REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

NSCLC

United States, France, Korea, Republic of
Regeneron Pharmaceuticals

Terminated

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Regeneron Pharmaceuticals

Completed

Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

Healthy

United States
Regeneron Pharmaceuticals

Recruiting

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Advanced NSCLC

United States
Regeneron Pharmaceuticals

Terminated

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

Pain | Osteoarthritis of the Knee

United States, Georgia, Moldova, Republic of, Poland, Ukraine
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Healthy Volunteer

Belgium
Regeneron Pharmaceuticals

Completed

An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Completed

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Healthy Volunteers

New Zealand
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

Sarcopenia

United States, Spain, Netherlands, France
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

Healthy Volunteers

United States
Regeneron Pharmaceuticals

Withdrawn

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

Healthy Volunteers | Birch Pollen Allergy

Belgium
Regeneron Pharmaceuticals

Completed

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Conjunctivitis | Allergic Rhinitis

Canada
Regeneron Pharmaceuticals

Completed

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Conjunctivitis | Allergic Rhinitis

United States, Belgium, Canada, Denmark, Germany
Regeneron Pharmaceuticals

Terminated

COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

COVID-19

United States
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Healthy Participants

United States, Moldova, Republic of, Romania
Regeneron Pharmaceuticals

Completed

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

COVID-19

United States
Regeneron Pharmaceuticals

Terminated

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

COVID-19

United States
Regeneron Pharmaceuticals

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

Healthy | Chronic Stable Illness

United States
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

COVID-19

United States, Mexico, Romania, Brazil, Chile, Moldova, Republic of
Regeneron Pharmaceuticals

Completed

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

Healthy | Chronic Stable Illness

United States
Regeneron Pharmaceuticals

Terminated

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Immunocompromised

United States, Mexico
Regeneron Pharmaceuticals

Terminated

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

SARS-CoV-2

United States
Regeneron Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

COVID-19

United States, Mexico, Romania
Regeneron Pharmaceuticals

No longer available

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

COVID-19
Luye Pharma Group Ltd.
Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Unknown

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Healthy Adults
Regeneron Pharmaceuticals

Active, not recruiting

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss (COURAGE)

Obesity

United States
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada

3

Subscribe